Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma | Zendy

S. Hescot | Zendy; Atmane Seck | Zendy; Maryse Guérin | Zendy; F Cockenpot | Zendy; Thierry Huby | Zendy; Sophie Broutin | Zendy; Jacques Young | Zendy; Angélo Paci | Zendy; Eric Baudin | Zendy; Marc Lombès | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma

Author(s) -

S. Hescot,

Atmane Seck,

Maryse Guérin,

F Cockenpot,

Thierry Huby,

Sophie Broutin,

Jacques Young,

Angélo Paci,

Eric Baudin,

Marc Lombès

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2080

Subject(s) - mitotane , adrenocortical carcinoma , chemistry , medicine , endocrinology , in vivo , lipoprotein , in vitro , apoptosis , cholesterol , ldl receptor , receptor , low density lipoprotein , cancer research , biochemistry , biology , microbiology and biotechnology

Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research